FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor…
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in…
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies…
TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech…
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis…
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults…
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a…
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Administrator Cole, you can fight illicit drugs and build a lawful, GMP-grade cannabinoid supply chain that shrinks the black market…